EMA Authorised: Hefiya (adalimumab) — Sandoz GmbH

View source ↗

Summary

EMA authorised Hefiya, a biosimilar adalimumab from Sandoz GmbH, for multiple inflammatory conditions including ankylosing spondylitis, hidradenitis suppurativa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Hidradenitis Suppurativa
• Juvenile Idiopathic Arthritis
• Psoriasis
• Uveitis

Drugs mentioned

• Hefiya (adalimumab)

Snippet

Status: Authorised. Therapeutic area: Spondylitis, Ankylosing;Hidradenitis Suppurativa;Psoriasis;Arthritis, Juvenile Rheumatoid;Uveitis. MAH: Sandoz GmbH. Decision date: 13/11/2025